Tamoxifen-Induced Steatohepatitis
Authors: Daniel S. Pratt
Journal: Annals of Internal Medicine (1995)

Letters1 August 1995Tamoxifen-Induced SteatohepatitisDaniel S. Pratt, Tamsin A. Knox, and John ErbanDaniel S. PrattNew England Medical Center; Boston, MA 02111., Tamsin A. KnoxNew England Medical Center; Boston, MA 02111., and John ErbanNew England Medical Center; Boston, MA 02111.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-3-199508010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Tamoxifen is one of the most commonly used oncologic therapeutic agents. Ongoing studies are evaluating the potential of tamoxifen as a chemopreventive agent for breast cancer; a reduction in the risk for development of cardiovascular disease and osteoporosis are being used as secondary end points in these studies. Although its overall safety record has been good, tamoxifen has been associated with endometrial cancer, retinopathy, and thromboembolic events. We report a case of tamoxifen-induced steatohepatitis.A 55-year-old woman had bilateral mastectomies for breast cancer. She began receiving tamoxifen after surgery. Results of liver function tests done before treatment ...References1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55:434-8. Google Scholar2. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. Gastroenterology. 1988; 95:1056-62. Google Scholar3. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990; 11:74-80. Google Scholar4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107:1103-9. Google Scholar5. Plowman PN. Tamoxifen as adjuvant therapy in breast cancer. Drugs. 1993; 46:819-33. Google Scholar Author, Article, and Disclosure InformationAffiliations: New England Medical Center; Boston, MA 02111. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver diseaseNAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and TreatmentMenopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic PerspectivesAPRI score non-invasive marker of metabolic syndrome in breast carcinoma patientsNASH in Nondiabetic Endocrine DisordersEstrogens and female liver healthHepatotoxicity in Patients with Metabolic Syndrome: Causes and ConsequencesThe Liver in OncologyThe Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast CancerDrug-induced hepatotoxicity in cancer patients - implication for treatmentNon-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio PretoDrug-induced fatty liver disease: An overview of pathogenesis and managementSmall-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and TamoxifenApplication of urine proteomics for biomarker discovery in drug-induced liver injuryProtective role of green tea extract against tamoxifen-induced liver injury in albino ratsDrug-Induced SteatohepatitisThe global NAFLD epidemicRaloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as a pro-oxidant agentCancer ChemotherapyAdverse Effects of Hormones and Hormone Antagonists on the LiverA Myriad of Pathways to NASHEstrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol dietLiver Disease Caused by DrugsThe association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancerRecent Developments in Liver PathologyA case–control study of non-alcoholic fatty liver disease in breast cancerTamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?Toremifene: An evaluation of its safety profileNASHDose Adaptation of Antineoplastic Drugs in Patients with Liver DiseaseDevelopment of an unbiased method for the estimation of liver steatosisPitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar−/−) miceDrug-induced steatohepatitisTamoxifen-Induced Nonalcoholic SteatohepatitisSerum leptin levels are associated with tamoxifen -induced hepatic steatosisEffects of Tamoxifen on Hepatic Fat Content and the Development of Hepatic Steatosis in Patients with Breast Cancer: High Frequency of Involvement and Rapid Reversal After Completion of Tamoxifen TherapyAGA technical review on nonalcoholic fatty liver diseaseHepatitis tóxica asociada al uso de tamoxifeno.Presentación de un caso y revisión bibliográficaEfficacy and Economics of Hormonal Therapies for Advanced Breast CancerTamoxifen-Induced Cirrhotic ProcessNonalcoholic steatohepatitisAltered expression of fatty acid–metabolizing enzymes in aromatase-deficient miceTamoxifen-induced transient multifocal hepatic fatty infiltrationSubacute Severe Steatohepatitis During Prednisolone Therapy for Systemic Lupus ErythematosisNonalcoholic fatty liver diseaseCirrhosis with steatohepatitis after adjuvant tamoxifenTamoxifen for retroperitoneal fibrosis.Tamoxifen 1 August 1995Volume 123, Issue 3Page: 236KeywordsAlcoholsBiopsyBreast cancerDrugsInflammationLiverLiver fibrosisLiver function testsNonalcoholic steatohepatitisSurgery Issue Published: 1 August 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...